Next Article in Journal
Iodine Status of Women of Reproductive Age in Sierra Leone and Its Association with Household Coverage with Adequately Iodized Salt
Next Article in Special Issue
Nanoscale Delivery of Resveratrol towards Enhancement of Supplements and Nutraceuticals
Previous Article in Journal
Supplementation with Guanidinoacetic Acid in Women with Chronic Fatigue Syndrome
Open AccessArticle

Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil
Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil
Author to whom correspondence should be addressed.
Nutrients 2016, 8(2), 73;
Received: 27 October 2015 / Revised: 22 December 2015 / Accepted: 20 January 2016 / Published: 29 January 2016
(This article belongs to the Special Issue Selected Papers from Resveratrol Regional Meeting 2015)
Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels. View Full-Text
Keywords: cardiovascular disease; cholesterol; resveratrol; schizophrenia cardiovascular disease; cholesterol; resveratrol; schizophrenia
Show Figures

Figure 1

MDPI and ACS Style

Zortea, K.; Franco, V.C.; Francesconi, L.P.; Cereser, K.M.M.; Lobato, M.I.R.; Belmonte-de-Abreu, P.S. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors. Nutrients 2016, 8, 73.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop